Recessive variants in ZNF142 cause a complex neurodevelopmental disorder with intellectual disability, speech impairment, seizures, and dystonia.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
11 2019
Historique:
received: 14 01 2019
accepted: 15 04 2019
pubmed: 1 5 2019
medline: 28 4 2020
entrez: 1 5 2019
Statut: ppublish

Résumé

The purpose of this study was to expand the genetic architecture of neurodevelopmental disorders, and to characterize the clinical features of a novel cohort of affected individuals with variants in ZNF142, a C Four independent research centers used exome sequencing to elucidate the genetic basis of neurodevelopmental phenotypes in four unrelated families. Following bioinformatic filtering, query of control data sets, and secondary variant confirmation, we aggregated findings using an online data sharing platform. We performed in-depth clinical phenotyping in all affected individuals. We identified seven affected females in four pedigrees with likely pathogenic variants in ZNF142 that segregate with recessive disease. Affected cases in three families harbor either nonsense or frameshifting likely pathogenic variants predicted to undergo nonsense mediated decay. One additional trio bears ultrarare missense variants in conserved regions of ZNF142 that are predicted to be damaging to protein function. We performed clinical comparisons across our cohort and noted consistent presence of intellectual disability and speech impairment, with variable manifestation of seizures, tremor, and dystonia. Our aggregate data support a role for ZNF142 in nervous system development and add to the emergent list of zinc finger proteins that contribute to neurocognitive disorders.

Identifiants

pubmed: 31036918
doi: 10.1038/s41436-019-0523-0
pii: S1098-3600(21)01056-X
pmc: PMC6821592
mid: NIHMS1530558
doi:

Substances chimiques

Trans-Activators 0
ZNF143 protein, human 0

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2532-2542

Subventions

Organisme : NIDDK NIH HHS
ID : P50 DK096415
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD042601
Pays : United States
Organisme : NIMH NIH HHS
ID : R01 MH106826
Pays : United States

Références

Cassandri M, Smirnov A, Novelli F, et al. Zinc-finger proteins in health and disease. Cell Death Discov. 2017;3:17071.
doi: 10.1038/cddiscovery.2017.71
Laity JH, Lee BM, Wright PE. Zinc finger proteins: new insights into structural and functional diversity. Curr Opin Struct Biol. 2001;11:39–46.
doi: 10.1016/S0959-440X(00)00167-6
Sun Y, Hu D, Liang J, et al. Association between variants of zinc finger genes and psychiatric disorders: systematic review and meta-analysis. Schizophr Res. 2015;162:124–137.
doi: 10.1016/j.schres.2015.01.036
Fattahi Z, Sheikh TI, Musante L, et al. Biallelic missense variants in ZBTB11 can cause intellectual disability in humans. Hum Mol Genet. 2018;27:3177–3188.
doi: 10.1093/hmg/ddy220
Cordeddu V, Redeker B, Stellacci E, et al. Mutations in ZBTB20 cause Primrose syndrome. Nat Genet. 2014;46:815–817.
doi: 10.1038/ng.3035
Mattioli F, Piton A, Gerard B, et al. Novel de novo mutations in ZBTB20 in Primrose syndrome with congenital hypothyroidism. Am J Med Genet A. 2016;170:1626–1629.
doi: 10.1002/ajmg.a.37645
Rasmussen MB, Nielsen JV, Lourenco CM, et al. Neurodevelopmental disorders associated with dosage imbalance of ZBTB20 correlate with the morbidity spectrum of ZBTB20 candidate target genes. J Med Genet. 2014;51:605–613.
doi: 10.1136/jmedgenet-2014-102535
Herve B, Fauvert D, Dard R, et al. The emerging microduplication 3q13.31: expanding the genotype-phenotype correlations of the reciprocal microdeletion 3q13.31 syndrome. Eur J Med Genet. 2016;59:463–469.
doi: 10.1016/j.ejmg.2016.08.010
Baxter AL, Vivian JL, Hagelstrom RT, et al. A novel partial duplication of ZEB2 and review of ZEB2 involvement in Mowat-Wilson syndrome. Mol Syndromol. 2017;8:211–218.
doi: 10.1159/000473693
Yuan H, Zhang L, Chen M, et al. A de novo triplication on 2q22.3 including the entire ZEB2 gene associated with global developmental delay, multiple congenital anomalies and behavioral abnormalities. Mol Cytogenet. 2015;8:99.
doi: 10.1186/s13039-015-0206-8
Buraniqi E, Moodley M. ZEB2 gene mutation and duplication of 22q11.23 in Mowat-Wilson syndrome. J Child Neurol. 2015;30:32–36.
doi: 10.1177/0883073814535501
Ghoumid J, Drevillon L, Alavi-Naini SM, et al. ZEB2 zinc-finger missense mutations lead to hypomorphic alleles and a mild Mowat-Wilson syndrome. Hum Mol Genet. 2013;22:2652–2661.
doi: 10.1093/hmg/ddt114
Domingo A, Erro R, Lohmann K. Novel dystonia genes: clues on disease mechanisms and the complexities of high-throughput sequencing. Mov Disord. 2016;31:471–477.
doi: 10.1002/mds.26600
Gabriele M, Vulto-van Silfhout AT, Germain PL, et al. YY1 haploinsufficiency causes an intellectual disability syndrome featuring transcriptional and chromatin dysfunction. Am J Hum Genet. 2017;100:907–925.
doi: 10.1016/j.ajhg.2017.05.006
Fuchs T, Gavarini S, Saunders-Pullman R, et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet. 2009;41:286–288.
doi: 10.1038/ng.304
Xiromerisiou G, Houlden H, Scarmeas N, et al. THAP1 mutations and dystonia phenotypes: genotype phenotype correlations. Mov Disord. 2012;27:1290–1294.
doi: 10.1002/mds.25146
Zakirova Z, Fanutza T, Bonet J, et al. Mutations in THAP1/DYT6 reveal that diverse dystonia genes disrupt similar neuronal pathways and functions. PLoS Genet. 2018;14:e1007169.
doi: 10.1371/journal.pgen.1007169
Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. Hum Mutat. 2015;36:928–930.
doi: 10.1002/humu.22844
Van der Auwera GA, Carneiro MO, Hartl C, et al. From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. Curr Protoc Bioinformatics. 2013;43:11 10 11–33.
Seelow D, Schuelke M, Hildebrandt F, Nurnberg P. HomozygosityMapper—an interactive approach to homozygosity mapping. Nucleic Acids Res. 2009;37:W593–599.
doi: 10.1093/nar/gkp369
Nellhaus G. Head circumference from birth to eighteen years. Practical composite international and interracial graphs. Pediatrics. 1968;41:106–114.
pubmed: 5635472
Zeng WQ, Al-Yamani E, Acierno JS Jr., et al. Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet. 2005;77:16–26.
doi: 10.1086/431216
Debs R, Depienne C, Rastetter A, et al. Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. Arch Neurol. 2010;67:126–130.
doi: 10.1001/archneurol.2009.293
Woods CG, Cox J, Springell K, et al. Quantification of homozygosity in consanguineous individuals with autosomal recessive disease. Am J Hum Genet. 2006;78:889–896.
doi: 10.1086/503875
Kervestin S, Jacobson A. NMD: a multifaceted response to premature translational termination. Nat Rev Mol Cell Biol. 2012;13:700–712.
doi: 10.1038/nrm3454
Lindeboom RG, Supek F, Lehner B. The rules and impact of nonsense-mediated mRNA decay in human cancers. Nat Genet. 2016;48:1112–1118.
doi: 10.1038/ng.3664
Bradshaw NJ, Porteous DJ. DISC1-binding proteins in neural development, signalling and schizophrenia. Neuropharmacology. 2012;62:1230–1241.
doi: 10.1016/j.neuropharm.2010.12.027
Papadopoulos JS, Agarwala R. COBALT: constraint-based alignment tool for multiple protein sequences. Bioinformatics. 2007;23:1073–1079.
doi: 10.1093/bioinformatics/btm076
Hempel M, Cremer K, Ockeloen CW, et al. De novo mutations in CHAMP1 cause intellectual disability with severe speech impairment. Am J Hum Genet. 2015;97:493–500.
doi: 10.1016/j.ajhg.2015.08.003
Kambouris M, Maroun RC, Ben-Omran T, et al. Mutations in zinc finger 407 [ZNF407] cause a unique autosomal recessive cognitive impairment syndrome. Orphanet J Rare Dis. 2014;9:80.
doi: 10.1186/1750-1172-9-80
Talkowski ME, Rosenfeld JA, Blumenthal I, et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell. 2012;149:525–537.
doi: 10.1016/j.cell.2012.03.028

Auteurs

Kamal Khan (K)

Center for Human Disease Modeling, Duke University Medical Center, Durham, NC, USA.
Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan.
Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad, Pakistan.

Michael Zech (M)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
Institut für Humangenetik, Technische Universität München, Munich, Germany.

Angela T Morgan (AT)

Murdoch Children's Research Institute and University of Melbourne Department of Paediatrics, Royal Children's Hospital, Parkville, Australia.

David J Amor (DJ)

Murdoch Children's Research Institute and University of Melbourne Department of Paediatrics, Royal Children's Hospital, Parkville, Australia.

Matej Skorvanek (M)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Tahir N Khan (TN)

Center for Human Disease Modeling, Duke University Medical Center, Durham, NC, USA.
Department of Biological Sciences, National University of Medical Sciences, Rawalpindi, Pakistan.

Michael S Hildebrand (MS)

Murdoch Children's Research Institute and University of Melbourne Department of Paediatrics, Royal Children's Hospital, Parkville, Australia.
Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC, Australia.

Victoria E Jackson (VE)

Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, and University of Melbourne Department of Medical Biology and School of Mathematics and Statistics, Parkville, VIC, Australia.

Thomas S Scerri (TS)

Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, and University of Melbourne Department of Medical Biology and School of Mathematics and Statistics, Parkville, VIC, Australia.

Matthew Coleman (M)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC, Australia.

Kristin A Rigbye (KA)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC, Australia.

Ingrid E Scheffer (IE)

Epilepsy Research Centre, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, VIC, Australia.
University of Melbourne Department of Paediatrics, Royal Children's Hospital, and Florey and Murdoch Children's Research Institute, Parkville, VIC, Australia.

Melanie Bahlo (M)

Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, and University of Melbourne Department of Medical Biology and School of Mathematics and Statistics, Parkville, VIC, Australia.

Matias Wagner (M)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
Institut für Humangenetik, Technische Universität München, Munich, Germany.

Daniel D Lam (DD)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.

Riccardo Berutti (R)

Institut für Humangenetik, Helmholtz Zentrum München, Munich, Germany.

Petra Havránková (P)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic.

Anna Fečíková (A)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic.

Tim M Strom (TM)

Institut für Humangenetik, Technische Universität München, Munich, Germany.
Institut für Humangenetik, Helmholtz Zentrum München, Munich, Germany.

Vladimir Han (V)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Petra Dosekova (P)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Zuzana Gdovinova (Z)

Department of Neurology, P.J. Safarik University, Kosice, Slovak Republic.
Department of Neurology, University Hospital of L. Pasteur, Kosice, Slovak Republic.

Franco Laccone (F)

Institute of Medical Genetics, Medical School of Vienna, Vienna, Austria.

Muhammad Jameel (M)

Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan.

Marie R Mooney (MR)

Center for Human Disease Modeling, Duke University Medical Center, Durham, NC, USA.

Shahid M Baig (SM)

Human Molecular Genetics Laboratory, Health Biotechnology Division, National Institute for Biotechnology and Genetic Engineering (NIBGE), Faisalabad, Pakistan.
Pakistan Institute of Engineering and Applied Sciences (PIEAS), Islamabad, Pakistan.

Robert Jech (R)

Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic.

Erica E Davis (EE)

Center for Human Disease Modeling, Duke University Medical Center, Durham, NC, USA.

Nicholas Katsanis (N)

Center for Human Disease Modeling, Duke University Medical Center, Durham, NC, USA. nicholas.katsanis@duke.edu.

Juliane Winkelmann (J)

Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany. juliane.winkelmann@tum.de.
Institut für Humangenetik, Technische Universität München, Munich, Germany. juliane.winkelmann@tum.de.
Lehrstuhl für Neurogenetik, Technische Universität München, Munich, Germany. juliane.winkelmann@tum.de.
Munich Cluster for Systems Neurology, SyNergy, Munich, Germany. juliane.winkelmann@tum.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH